An interpretable rule-based diagnostic classification of diabetic nephropathy among type 2 diabetes patients by unknown
PROCEEDINGS Open Access
An interpretable rule-based diagnostic
classification of diabetic nephropathy among
type 2 diabetes patients
Guan-Mau Huang1, Kai-Yao Huang1, Tzong-Yi Lee1,2, Julia Tzu-Ya Weng1,2*
From The Thirteenth Asia Pacific Bioinformatics Conference (APBC 2015)
HsinChu, Taiwan. 21-23 January 2015
Abstract
Background: The prevalence of type 2 diabetes is increasing at an alarming rate. Various complications are
associated with type 2 diabetes, with diabetic nephropathy being the leading cause of renal failure among
diabetics. Often, when patients are diagnosed with diabetic nephropathy, their renal functions have already been
significantly damaged. Therefore, a risk prediction tool may be beneficial for the implementation of early treatment
and prevention.
Results: In the present study, we developed a decision tree-based model integrating genetic and clinical features
in a gender-specific classification for the identification of diabetic nephropathy among type 2 diabetic patients.
Clinical and genotyping data were obtained from a previous genetic association study involving 345 type 2
diabetic patients (185 with diabetic nephropathy and 160 without diabetic nephropathy). Using a five-fold cross-
validation approach, the performance of using clinical or genetic features alone in various classifiers (decision tree,
random forest, Naïve Bayes, and support vector machine) was compared with that of utilizing a combination of
attributes. The inclusion of genetic features and the implementation of an additional gender-based rule yielded
better classification results.
Conclusions: The current model supports the notion that genes and gender are contributing factors of diabetic
nephropathy. Further refinement of the proposed approach has the potential to facilitate the early identification of
diabetic nephropathy and the development of more efficient treatment in a clinical setting.
Background
Diabetes is a metabolic disorder characterized by the
inability of the pancreas to produce enough insulin or
the body’s lack of ability to effectively use insulin. The
disease is contributed by multiple factors, including diet,
lifestyle, and genes. Despite the advancement in health-
care, the prevalence of diabetes is still on the rise. More
than 150 million people worldwide are affected with this
debilitating disease [1]. Thus, the surveillance, preven-
tion, and control of diabetes and its complications are
becoming increasingly important.
Diabetes can result in various complications, damaging
the heart, blood vessels, eyes, kidneys, and nerves. As one
of the major microvascular complications of diabetes,
diabetic nephropathy affects about 30% of the people
with type 1 diabetes (T1D), and 25-40% of the people
with type 2 diabetes (T2D) [2]. DN is characterized by
the persistent elevated levels of albumin in the urine, pro-
gressive decline in the glomerular filtration rate, and
increased arterial blood pressure. In fact, DN is among
the leading causes of end stage renal disease (ESRD),
imposing serious impact on morbidity, mortality and the
patients’ quality of life [2]. Compared to non-diabetics,
the likelihood of dying from renal disease is 17 times
greater for diabetics [3].
* Correspondence: julweng@saturn.yzu.edu.tw
1Department of Computer Science and Engineering, Yuan Ze University,
Chung-Li, Taiwan
Full list of author information is available at the end of the article
Huang et al. BMC Bioinformatics 2015, 16(Suppl 1):S5
http://www.biomedcentral.com/qc/1471-2105/16/S1/S5
© 2015 Huang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Generally, DN symptoms are not obvious. In T1D
patients, DN develops over an initial 10 to 15 years of dia-
betes; whereas in T2D patients, the onset is less clearly
defined [4]. When clinical indices for renal functions (e.g.
urinary protein level) become abnormal, the kidneys have
already been significantly damaged and prevention against
ESRD may be too late at this stage [5]. Thus, it would be
beneficial to develop a prediction model utilizing various
clinical measures, such as gender, history of diabetes, body
mass index (BMI), etc. In addition, since existing studies
suggest that genes and gender play specific and significant
roles in DN [3,6,7], integrating genetic and gender infor-
mation in the prediction of DN susceptibility may lead to
more effective prevention or treatment.
To date, two groups have attempted to construct predic-
tion models for DN. Cho et al. (2007) utilized a support
vector machine (SVM) approach to classify DN patients
among type 2 diabetics, but the model was trained on an
irregular and unbalanced dataset [8]. On the other hand,
Leung et al. compared various machine learning and statis-
tical methods to develop a prediction strategy for the iden-
tifcation of genotype-phenotype risk patterns in DN [9].
Combining genotype and clinical information as features
for classification through SVM and random forest
approaches was found to generate the best performance
[9]. However, as diabetes and DN are caused by multiple
factors [1,3,7], a model designed for one community may
not be applicable to another. Moreover, prediction results
generated from computational algorithms may be difficult
for clinicians to explain to patients regarding their risk of
developing DN and convince the patients to take the neces-
sary preventative measures. Therefore, a straightforward
and user-friendly tool is more practical in a clinical setting.
Previously, Wu et al. [10,11] have conducted a candidate
gene analysis on 345 T2D patients, analyzing the associa-
tion of 20 candidate genes with T2D, as well as the related
complications such as obesity and DN. Through the gener-
alized multi-dimensional reduction approach, Wu et al.
have identified various gene-gene interactions that may
represent genetic susceptibilities to T2D, obesity, and DN
[10,11]. The findings suggest that T2D and DN may be
attributable to multiple factors that include the interactions
between specific genes and the environment.
In the present study, we employed a gender-based rule
in a decision tree approach to identify the risk for DN
among T2D patients using the data provided by Wu et al
[10,11]. Similar to Leung et al.’s finding (2013), our results
indicate that the integration of clinical and genetic features
yielded better performance in distinguishing DN from
non-DN diabetic patients [9]. Furthermore, the nature of
decision tree classification may help simplify interpretation
of the results. This easy-to-understand prediction tool may
be beneficial for the early detection of T2D patients sus-
ceptible to DN.
Results
Performance comparison between individual and
combinations of clinical features
The performance of using individual clinical features for
DN classification analysis is shown in Tables S3-S12.
Among the clinical attributes, blood creatinine (BC),
blood urinary nitrogen (BUN), and urinary albumin
were the three renal indices that generate the best per-
formance (Table 1). In contrast, other clinical features
that do not directly reflect kidney functions, including
serum triglyeride level and high-density lipoprotein
(HDL) level, were much lower in accuracy, specificity,
and sensitivity. For the purpose of prediction, we
decided to exclude direct kidney function indicators for
subsequent analyses (Additional file 2: S3-S12).
In order to assess whether feature selection would
enhance the classification performance, each features were
evaluated based on their information gain (Table S7) or
F-scores (Table S8). Table 2 shows the classification per-
formance of implementing variable numbers of the top
ranking features in different classifiers. The best accuracy,
sensitivity, and specificity were achieved by the three-, six-,
and seven-attribute model in SVM, random forest, and
Naïve Bayes, as well as decision tree, respectively. Overall,
the performance was slightly better than using individual
clinical features for classification, but it was still much
lower compared to that of BC, BUN, or urinary albumin.
Performance comparison between individual and
combinations of genetic features
We followed the same procedures to evaluate the possibi-
lity of employing genotype information from the 20 can-
didate genes in DN classification. Compared to the
clinical attributes, individual genetic features performed
poorly, with accuracy, specificity, and sensitivity mea-
sures ranging from 48% to 57%, 36% to 100%, and 0% to
69%, respectively (Tables 3 and S13-S16). The result was
similar when we attempted to select the best features by
information gain and F-score analyses (Table S17 and
S18), and compared the performance of using various
top-ranking attributes in different classifiers (Tables 4
and S19-S22). The best performance was achieved when








Urinary albumin 96.23% 95.36% 95.49% 95.13%
BUN 85.51% 82.90% 82.61% 79.57%
BC 83.19% 80% 84.72% 81.30%
Serum
triglyceride
60.87% 56.53% 57.89% 59.57%
HDL 63.91% 62.32% 59.13% 55.22%
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four, 12, and 13 genetic features were implemented to
construct the prediction model via decision tree, random
forest, and SVM, as well as Naïve Bayes, respectively.
Nevertheless, similar to using various combinations of
clinical features for classification, the improvement in
performance was marginal (Additional file 3: S13-S22).
Performance evaluation on the integration of clinical and
genetic features for DN classification
Perhaps by looking at clinical and genetic features sepa-
rately, we have ignored the possible interactions among
genes and clinical traits that underlie the disease
mechanisms of DN. Thus, we tried integrating both
clinical and genetic attributes for classification. First, the
best features were selected based on their corresponding
information gain and F-scores (Table S23 and S24).
Then, the top ranking clinical and genetic features were
integrated for performance evaluation in different classi-
fiers. Overall, a slight increase in performance was
observed (Tables 5 and Additional file 4: S23-S28)
In particular, when 25 of the 32 features were utilized
for classification, random forest appeared to generate the
best results. Decision tree seemed to be the second best
classifier, when features including serum triglyceride,
ADRB2, ENPP1 (ectonucleotide pyrophosphatase/phos-
phodiesterase 1), gender, fasting plasma glucose, TCF7L2
(transcription factor 7-like 2), ADIPOQ (adiponectin,
C1Q and collagen domain containing protein) were
employed for classification. This approach appeared to
outperform previous attempts using clinical or genetic
features separately. Yet, the classification performance
was still much lower compared to renal function markers
such as urinary albumin, BC and BUN (Table 1).
Optimization of DN classification performance by the
implementation of a gender-based rule
Based on these results, we decided that decision tree and
random forest worked best with our data. However, our
objective was to construct an interpretable classification
model that can be easily applied in a clinical setting. In
this case, decision tree holds an advantage over random
forest as the former classifies individuals among a range of
numerical and categorical features, following certain set
rules in a way that is similar to human decision making.
The latter, on the other hand, is not as easy to interpret
because trees are arbitrarily added to the forest. Therefore,
we focused on using decision tree for subsequent classifi-
cation attempts.
Since genes and gender are known contributing factors
to DN risk [3,6,7], we postulated that the features required
to discriminate DN among T2D patients may be different
between males and females. Thus, we implemented a gen-
der-based rule, separating the training data based on gen-
der prior to classification. When applied on the training
data and assessed with a five-fold cross validation
approach, the proposed method yielded better classifica-
tion results with the decision tree model (Table 6), with
accuracy, specificity, and sensitivity reaching 85.27%, 83.32
and 85.24%, respectively. On a separate testing dataset
(Table 7), the classification accuracy, specificity, and










FTO 57.39% 51.01% 47.83% 56.52%
ENPP1 55.22% 53.91% 49.13% 55.22%
ADIPOQ 53.48% 53.04% 55.22% 53.48%
GHSR
(rs9819506)
53.48% 53.04% 47.83% 53.48%
GHSR (rs490683) 53.91% 53.04% 47.52% 52.17%
The GHSR gene is represented by two SNP IDs.
Table 4 Performance of utilizing variable numbers of












4 60.43 54.70 66.37
Random
forest
12 53.91 59.83 47.79
SVM 13 53.04 67.65 31.9
Naïve Bayes 13 56.09 58.12 53.98
Table 5 Performance of utilizing variable numbers of












7 65.22 63.25 67.26
Random
forest
25 65.09 60.68 71.68
SVM 7 61.23 66.17 51.06
Naïve Bayes 10 63.91 46.15 82.30
Table 2 Performance of utilizing variable numbers of












7 62.17 55.56 69.02
Random
forest
6 63.91 60.68 67.26
SVM 3 60.87 50 78.72
Naïve Bayes 7 62.61 41.03 84.96
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sensitivity were 78.50%, 80.64 and 81.40%, respectively.
Performance evaluation of the other classifiers are shown
in Tables S29-S31. Note that, for males with more than
17 years of diabetic history, none of the features, except
for urinary albumin, could accurately predict DN (Addi-
tional file 5: S29-S31).
The gender-based classification approach resulted in
substantially enhanced performance compared to using
individual clinical features, genetic features, or the com-
bination of these two types of attributes. Figures 1A and
1B show the way that male and female diabetic patients
would be classified in our decision tree model for DN
identification. Red and green colors indicate DN and
non-DN, respectively. Accuracy measures are repre-
sented by the intensity of the colors.
Although the performance of the proposed gender-
based strategy may not exceed that of renal function mar-
kers, the model presents an easily interpretable classifica-
tion tree for DN prediction. For example, in Figure 1B, a
female patient with BMI less than 24 and serum triglycer-
ide level greater than 134 mg/dl, may very likely be
susceptible to DN if she exhibits a GG genotype on the
IGF2BP2 (insulin-like growth factor 2 mRNA binding pro-
tein 2) gene. In contrast, if she possesses the TT genotype,
her possibility of developing DN is relatively low. How-
ever, if she is heterozygous at this locus (i.e. the GT geno-
type), the next determining factor of whether or not she
belongs to the high-risk group would be her fasting plasma
glucose level. Thus, the constructed model may make it
easier for clinicians to efficiently identify DN risk among
T2D patients based on their clinical examination results as
well as their genetic susceptibility.
Discussion
Multiple environmental and genetic factors affect the dis-
ease progression of diabetes and its associated kidney
complications [3,7,12], leading to various chronic and
complex health problems. The aim of the present study
was to develop a systematic risk assessment model that
aid clinicians in the identification of DN patients to facili-
ate effective monitoring and efficient use of medical
resources. As the purpose was to assess the possibility of
Table 6 Performance of gender-based decision tree classification of diabetic nephropathy in the training dataset
Group Feature SN(%) SP(%) ACC(%)


















5. Male, history>17(years) Urinary albumin 96.88 100 97.06
Table 7 Performance of gender-based decision tree classification of diabetic nephropathy in the testing dataset
Group Feature SN(%) SP(%) ACC(%)


















5. Male, history>17(years) Urinary albumin 100 100 100
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early prevention, parameters directly associated with
renal functions, such as blood creatinine (BC), blood
urinary nitrogen (BUN), and urinary albumin, were
removed. Under these conditions, our study focused on
analyzing the performance of utilizing various clinical
(excluding direct renal function markers) and genetic
attributes, as well as the integration of a gender-based
rule in a decision tree to classify DN patients in a T2D
dataset.
Our present finding supports the notion that mechan-
isms underlying DN may be attributable to multiple
genetic and environmental factors. When individual
genetic or clinical attributes were employed in the classi-
fication of DN patients from the T2D data, the perfor-
mance was, however, disappointing. A slight increase in
performance was achieved after the clinical and genetic
features were combined for classification. The results
correspond with existing observations that each genetic
and environmental determinant may contribute moder-
ate effects to DN, but when interacting together, these
factors may significantly influence the progression of DN
in T2D patients [13].
Therefore, when making predictions on the develop-
ment of DN for T2D patients, it may be important to
consider both genetic and clinical factors. In fact, many
chronic disease-related studies also agree on the integra-
tion of clinical and genetic parameters in making better
predictions about disease risks [9,14,15]. For complex
diseases like T2D and its associated DN complication
that are genetically heterogeneous, the same genetic fea-
tures that may help predict DN susceptibility for one
patient may not apply to everyone. However, classifying
individuals based on clinical and genetic differences may
present to be a logical solution.
Unlike existing models [8,9], we implemented a gen-
der-based rule in the decision tree classification of DN.
The SVM prediction tool introduced by Cho et al. [8]
was built on unbalanced datasets. While Leung et al.’s
model achieved almost 100% accuracy in the prediction
of T2D kidney diseases as a result of training their model
on a much bigger sample size [9], their tool is also
derived from SVM. Despite being the most effective at
handling numeric data, the result of an SVM analysis is
not necessarily “clinician or patient friendly,” potentially
inhibiting it from being widely applied in clinical settings.
In contrast, the simplicity of decision tree learning, in
addition to its ability to handle both non-homogeneous
and nonlinear data in common clinical situations where
outliers, missing attribute values, or misclassified points
exist, becomes an advantage [16]. Moreover, the results
generated by decision tree-based methods are easy to
interpret as the approach discovers if-then rules from a
given dataset. Most of these merits may not be easily
attainable by conventional classification methods such as
linear discrimination analysis or k-nearest neighbor
method. Although our attempts on classifying DN based
on the combination of clinical and genetic parameters
failed to outperform common renal funtion indices, by
implementing a gender-based rule which follows existing
observations that DN risk differs between males and
females [7,12,17], we were able to increase the perfor-
mance of DN identification significantly.
Our approach provides additional support for the
emerging evidence that DN risk is gender-specific. For
example, for female patients, BMI, serum triglyceride
level, fasting plasma glucose level, the IGF2BP2 gene
were the features that best discrminate DN from non-DN
individuals. It is known that the level of triglycerides is
Figure 1 Decision tree classification of diabetic nephropathy among male and female type 2 diabetics. Accuracy measures are
represented by the color intensity. Red indicates 100% prediction accuracy for DN. Pink indicates a prediction accuray above 80% but below
100% for DN. Green indicates 100% prediction accuracy for non-DN. Light green indicates a prediction accruacy above 80% but below 100% for
non-DN.
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higher in DN patients with T1D [18] and T2D [19]. In
addition, the IGF2BP2 gene has been associated with DN
in males with T1D [20] and appears to modulate the risk
of T2D among obese individuals of the Chinese Han
population [21]. Although, currently, there is insufficient
evidence correlating the IGF2BP2 gene with DN in T2D
females, our model suggests that female patients with the
TT genotype at the IGF2BP2 gene locus may be at a
lower risk of developing DN compared to those with the
GG genotype.
Likewise, according to our analysis, the primary deter-
mining factors for the development of DN for male T2D
patients lie in the duration of T2D and serum triglyceride
level. Different genes appear to act on the risk of DN for
males with different durations of T2D. For instance,
males with 11 to 17 years of T2D history, would very
likely develop DN if they have moderately high levels of
serum triglyceride and possess the CC genotype at the
ADIPOQ gene locus. In contrast, those heterozygous at
this gene locus must exhibit high fasting plasma glucose
levels to have increased risk of developing DN. Though
the ADIPOQ gene has been associated with T2D [22,23]
and DN [11], the exact nature of this association has not
been identified. Our results imply that the ADIPOQ gene
may exert its effect on DN risk among individuals with
specific clinical attribute values. In addition, our model
suggests that for males that have lived with T2D for less
than 11 years, if they are heterozygous at the obesity and
T2D candidate gene, FTO (fat mass and obesity asso-
ciated) [24], they are more likely to develop DN when
their LDL levels exceed 100 mg/dl.
Conclusions
To our knowledge, as the disease mechanisms of DN are
complex and the symptoms are not obvious, there are no
accurate and easy-to-interpret diagnostic methods for the
early screening of DN susceptibility. By performing a ser-
ies of decision tree analyses with the integration of a gen-
der-based rule, we have identified specific clinical and
genetic features, as well as their hidden associations and
interactions, that may be used for DN risk assessment.
The proposed strategy generates results that are easy-to-
interpret and easy-to-implement. With further refine-
ment in parameter settings and testing in a bigger sample
size, our approach may have the potential to facilitate
early identification of individuals with DN susceptibility
and therefore, efficient prevention or treatment for DN.
Methods
Participants
The T2D data were kindly provided by Dr. L.S.H. Wu.
The data consisted of 345 Taiwanese patients recruited
from the Tri-Service General Hospital in Taipei, Taiwan,
in 2002. These data were obtained in previously pub-
lished studies under the approval of the insititutional
review board at the the Tri-Service General Hospital
Taipei,Taiwan. The criteria for recruitment has been
described in Wu et al. [10,11]. All recruited patients ful-
filled the following criteria: (1) diagnosed with diabetes
for >5 years; (2) age 30 to 75 years; (3) The fasting plasma
glucose was >6.93 mmol/l (126 mg/dl); (4) The glycated
haemoglobin (HbA1C) was >6%. Patients who were clas-
sified as the DN group fulfilled any of the following three
criteria: (1) the average ACR was >300 μg/mg; (2) the
BUN was >20 mg/dl; and (3) the serum creatinine was
>1.7 mg/dl. The rest of the patients were classified as the
T2D without DN group. The case group comprises 185
T2D patients with DN, and the control group comprised
160 T2D without DN. Table S1 (Additional file 1) pro-
vides an differences in demographic and clinical charac-
teristics among the participants were assessed via
Student’s t-test. The p-value < 0.05 was regarded as sta-
tistically significant. In Wu et al [10,11], genotypes on the
20 T2D candidate genes have already been determined,
and the genotype distribution for each gene is shown in
Table S2 (Additional file 1).
System flow
The system flow of our work is illustrated in Figure 2.
Our data were divided into three parts: 2/3 as the train-
ing and 1/3 as the testing dataset. The training dataset
was composed of 117 positive and 113 negative data,
while the testing dataset consisted of 68 positive and 47
negative data. Features were selected based on their cor-
responding information gain scores for decision tree and
naïve Bayes, or F-scores for SVM. A five-fold cross-vali-
dation analysis was conducted to assess the performance
of the following strategies in classifying DN by the deci-
sion tree, random forest, libsvm and naïve Bayes
approaches: 1) selected clinical features only, 2) selected
genetic features only, 3) combinations of clinical and
genetic features, 4) a gender-based rule integrated with
selected clinical and genetic features.
Feature selection
Experiments were conducted in LibSVM (version 3.12)
[25] and WEKA, or Waikato Environment for Knowledge
Analysis (version 3.6.5) [26], a JAVA based platform for
data mining and data analysis. Since diabetes and its
associated complications can be caused by multiple fac-
tors [12,17], the best features from our dataset for DN
classification were identified by computing the F-scores
in LibSVM for SVM, and the information gain scores via
the InfoGainAttribute in WEKA [27] for decision tree
and naïve Bayes. Features were subsequently ranked
based on these scores.
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F-score
F-score [28] is a feature selection technique that mea-
sures the extent by which a certain attribute can discri-
minate a dataset into different classes. Given training
vectors xk, k = 1,2,3...,m, if n- and n+ denote the number
of positive and negative instances, respectively, then the
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, respectively. x(+)k,i indicates the i-th feature
of the k- th positive instance, while x(−)k,i is the ith fea-
ture of the kth negative instance. Features with larger
F-scores are more discriminative.
Information gain
The InfoGainAttribute tool in WEKA presents a simple
feature selection algorithm that evaluates the ability of
an attribute in making accurate and specific classifica-
tion in a dataset by measuring its information gain
according to the following formula:




where information gain IG(A) is the measure of the
difference in entropy from before to after the dataset S
is split by an attribute A, and t represents the subsets
created from the splitting, such that S =
⋃
t∈T t, and p(t)
is the proportion of the number of elements in t to the
number of elements in dataset S. H is the information






where S is the dataset for which entropy is being cal-
culated, × represents the classes in S, and p(x) is the
proportion of the number of elements in class × to the
number of elements in set S.
Figure 2 System flow of diabetic nephropathy analysis.
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Decision tree learning algorithm
Next, we used the C4.5 decision tree algorithm [29] in
WEKA to perform DN classfication. The C4.5 algorithm
incorporates the concept of information gain to generate
the best tree for classification and has become a stan-
dard learning tool for the supervised classification pro-
blem domain. C4.5 is an extension of the ID3 decision
tree induction algorithm [30] with additional features,
including the ability to manage continuous attribute
values and noise, deriving alternative measures for
selecting attributes, and pruning tees [29]. Tree induc-
tion in C4.5 involves the following three steps [31]: 1)
construction of a large tree from the training data
according to attribute selection by information gain
scores; 2) removal of branches to avoid overfitting; 3)
processing of the pruned tree to enhance its interpret-
ability. The performance of each generated tree was
evaluated by five-fold cross-validation.
SVM
SVM is a machine learning algorithm which attempts to
find a hyperplane that best differentiate the data into one
category or the other [32]. It is often used for classifica-
tion, regression, and other learning tasks. We selected
the features according to their corresponding F-scores
and performed classification based on the higher ranking
features via SVM in LIBSVM [25].
Naïve Bayes
Naïve Bayes, coupled with information gain analysis as
the feature selection method, was evaluated for its perfor-
mance in classifying DN and non-DN patients in the
T2D dataset. Naïve Bayes [33,34] is generally used for
text classification due to its computational efficiency and
relatively good predictive performance. The formula of
Naïve Bayes follows Baye’s theorem of probability:
P (Ck|x) = P(Ck) × P(x|Ck)P(x)
where P(C = Ck|X = x) is the probability that an item
belongs to class Ck, given that Ck has a feature vector x.
Having made clear that Ck and × are values taken on by
random variables C and × simplify notation by omitting
those random variables. For instance, the expected num-
ber of classification errors can be minimized by assign-
ing a document with feature vector × to the class Ck for
which P(Ck|x) is high.
Random forest
Random forest was also included in our study as one of
the classifiers for building the DN prediction model.
The random forest algorithm [35] outputs a collection
of decision trees based on the random selection of
features. Individual trees may exhibit specific prediction
errors. However, when aggregated, it is expected that
each tree can capture different patterns within the data
and generate better performance [36].
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Additional file 2: Table S3-S12: Performance of individual or selected
clinical features for diabetic nephropathy classification. This file can
be viewed with: Microsoft Excel Viewer Table S3. Performance of
individual clinical features for diabetic nephropathy classification via
decision tree. Table S4. Performance of individual clinical features for
diabetic nephropathy classification via random forest Table S5.
Performance of individual clinical features for diabetic nephropathy
classification via SVM. Table S6. Performance of individual clinical
features for diabetic nephropathy classification via Naïve Bayes. Table S7.
Ranking of the 12 clinical features based on their information gain scores
Table S8. Ranking of the 12 clinical features based on their F-scores
Table S9. Performance of using variable numbers of clinical features to
predict diabetic nephropathy via decision tree. Table S10. Performance
of using variable numbers of clinical features to predict diabetic
nephropathy via random forest. Table S11. Performance of using
variable numbers of clinical features to predict diabetic nephropathy via
SVM. Table S12. Performance of using variable numbers of clinical
features to predict diabetic nephropathy via Naive Bayes.
Additional file 3: Table S13-S22: Performance of individual and
selected genetic features for diabetic nephropathy classification
This file can be viewed with: Microsoft Excel Viewer Table S13.
Performance of individual genetic features for diabetic nephropathy
classification via decision tree. Table S14. Performance of individual
genetic features for diabetic nephropathy classification via random forest.
Table S15. Performance of individual genetic features for diabetic
nephropathy classification via SVM. Table S16. Performance of individual
genetic features for diabetic nephropathy classification via Naïve Bayes.
Table S17 Ranking of the 20 genetic features based on their information
gain scores. Table S18. Ranking of the 20 genetic features based on
their F-scores. Table S19. Performance of using variable numbers of
genetic features to predict diabetic nephropathy via decision tree. Table
S20. Performance of using variable numbers of genetic features to
predict diabetic nephropathy among type 2 diabetics via random forest.
Table S21. Performance of using variable numbers of genetic features to
predict diabetic nephropathy via SVM. Table S22. Performance of using
variable numbers of genetic features to predict diabetic nephropathy via
Naive Bayes.
Additional file 4: Table S23-S28: Performance of utilizing clincal and
genetic features for diabetic nephropathy classification. This file can
be viewed with: Microsoft Excel Viewer Table S23. Ranking of all
clinical and genetic features based on their information gain scores.
Table S24. Ranking of all clinical and genetic features based on their F-
scores Table S25. Performance of using variable numbers of genetic and
clinical features to predict diabetic nephropathy via decision tree. Table
S26. Performance of using genetic and clinical features to predict
diabetic nephropathy via random forest. Table S27. Performance of
using genetic and clinical features to predict diabetic nephropathy via
SVM. Table S28. Performance of using genetic and clinical features to
predict diabetic nephropathy via Naive Bayes.
Additional file 5: Table S29-S31: Performance of gender-based
diabetic nephropathy classification. This file can be viewed with:
Microsoft Excel ViewerTable S29. Performance of gender-based
random forest classification of diabetic nephropathy in the training/
testing dataset. Table S30. Performance of gender-based SVM
classification of diabetic nephropathy in the training/testing dataset.
Table S31. Performance of gender-based Naïve Bayes classification of
diabetic nephropathy in the training/testing dataset.
Additional file 1: TableS 1-S2: Demographic and clinical
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characteristics of the participants. Table S2. Genotype distributions of the
significant candidate genes in T2D patients with and without diabetic
nephropathy.
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